Pacira Pharmaceuticals Stock
Price
Target price
€27.00
€27.00
-
-
-
€47.53
10.05.24 / Stuttgart Stock Exchange
WKN: A1H68T / Symbol: PCRX / Name: Pacira Pharma / Stock / Pharmaceuticals / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pacira Pharmaceuticals Stock
With 18 Buy predictions and not the single Sell prediction the community is currently very high on Pacira Pharmaceuticals.
With a target price of 47 € there is a hugely positive potential of 74.07% for Pacira Pharmaceuticals compared to the current price of 27.0 €.
Pros and Cons of Pacira Pharmaceuticals in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pacira Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pacira Pharmaceuticals | - | 8.000% | 8.871% | -28.947% | -9.396% | -46.535% | -35.545% |
| Rockwell Medical Inc. | 3.270% | -3.934% | 1.475% | -38.828% | -12.687% | -81.661% | -97.013% |
| Avid Bioservices Inc | -3.230% | -1.961% | 17.188% | -53.704% | 22.951% | -54.545% | 130.167% |
| Gritstone Oncology Inc | -0.140% | -18.396% | -7.911% | -66.397% | -60.845% | -89.818% | - |
Comments
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Barclays PLC from $40.00 to $38.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Needham & Company LLC from $45.00 to $43.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PCRX provided by MarketBeat